ArticleBriefings in bioinformatics2026
BRIDGE-KO: auditable transfer learning with bridged knockoffs improves cross-cohort microbiome prediction of immunotherapy response.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Transfer learning promises to reuse AI models across biomedical studies, but it often fails when differences between datasets introduce cohort-specific artifacts and 'negative transfer.' We present BRIDGE-KO, an interpretable deep-learning framework that turns transfer learning into a testable design process by asking: where to transfer from (source-target coverage and proximity), what to transfer (which representation level is most portable), and how to harmonize data to reduce technical confounding. BRIDGE-KO creates source-preserving knockoffs-synthetic 'shadow' features that capture the source dependency structure-and bridges them to a fixed target cohort, providing built-in baselines that flag non-portable signal. Applied to predicting immune checkpoint inhibitor response, transferring gut microbiome profiles from MicroBioMap (n = 168,464) to melanoma immune checkpoint inhibitor cohorts (n = 154), naive baselines performed near chance (AUC ≈ 0.52), whereas batch correction plus proximity-aware transfer improved performance (AUC = 0.67, 10 splits). BRIDGE-KO also enables an interpretable responder-specific audit of microbiome remodeling via correlation-shift spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.